We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Supplemental NDA Submitted for Gleevec

Dec 1, 2001
Volume: 
10
Issue: 
12
  • Chronic Myeloid Leukemia

EAST HANOVER, NJ—Novartis has submitted a supplemental new drug
application (sNDA) to the FDA seeking approval for Gleevec (imatinib mesylate)
for the treatment of patients with unresectable and/or metastatic malignant
gastrointestinal stromal tumors (GISTs). Last May, Gleevec received FDA
approval for the treatment of patients with chronic myeloid leukemia in the
blast crisis, accelerated phase, or in chronic phase after failure of
interferon-alfa.

The submission is supported by data from a phase II, open-label study of 147
patients with unresectable or metastatic malignant GIST randomized to receive
400 mg or 600 mg of Gleevec daily for up to 24 months. The overall response
rate is 40%, the company said, based on confirmed partial responses at the time
of the data cut-off for the submission. An additional 32% of patients achieved
a clinically significant reduction in tumor size. Only 12% progressed. 

Related Articles

  • BCR-ABL1 Levels Can Predict Sustained Deep Molecular Response in CML
  • FDA Approves New Frontline Drug for Chronic-Phase CML
  • FDA Approves New Option for Childhood Leukemia
  • Responses Better With Bosutinib vs Imatinib in Untreated CML
  • Radotinib for CML Yields Better Responses Than Imatinib

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.